293 results on '"Vissing, John"'
Search Results
2. Low skeletal muscle mass and liver fibrosis in children with cerebral palsy
3. OxPhos defects cause hypermetabolism and reduce lifespan in cells and in patients with mitochondrial diseases
4. Glycogen storage diseases
5. Data from the European registry for patients with McArdle disease (EUROMAC): functional status and social participation
6. Muscle fat replacement and contractility in patients with skeletal muscle sodium channel disorders
7. Natural history of cardiac involvement in myotonic dystrophy type 1 – Emphasis on the need for lifelong follow-up
8. Skeletal Muscle Involvement in Patients With Truncations of Titin and Familial Dilated Cardiomyopathy
9. Acetaminophen treatment in children and adults with spinal muscular atrophy: a lower tolerance and higher risk of hepatotoxicity
10. Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study
11. Fatigue and associated factors in 172 patients with McArdle disease: An international web-based survey
12. Myosin ATPase inhibition fails to rescue the metabolically dysregulated proteome of nebulin-deficient muscle
13. Quality of life in hypokalemic periodic paralysis – a survey
14. Homozygous splice variant (c.1741-6G>A) of the COL6A1 gene in three patients with Ullrich congenital muscular dystrophy
15. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
16. Can a modified ketogenic diet be a nutritional strategy for patients with McArdle disease? Results from a randomized, single-blind, placebo-controlled, cross-over study
17. Causes of symptom dissatisfaction in patients with generalized myasthenia gravis
18. Diagnostic interest of whole-body MRI in early- and late-onset LAMA2 muscular dystrophies: a large international cohort
19. Hemoglobin concentration and blood shift during dry static apnea in elite breath hold divers
20. Clinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post-hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study (P4-11.001)
21. Response to Rozanolixizumab Across Treatment Cycles in Patients with Generalized Myasthenia Gravis: A Post-hoc Analysis (P10-11.005)
22. Drivers of New Rozanolixizumab Treatment Cycles in Patients with Generalized Myasthenia Gravis in the Phase 3 MycarinG and Open-label Extension Studies (P10-11.003)
23. Classical Pathway Inhibition with Anti-active C1s Antibody DNTH103 Prevents Neurotransmission Impairment in a Preclinical Model of Myasthenia Gravis (S15.001)
24. Achievement of Minimal Symptom Expression and Effect on Disease-specific Measures in Acetylcholine Receptor Antibody-positive Participants with Generalized Myasthenia Gravis Treated with Efgartigimod in ADAPT/ADAPT+ (P10-11.009)
25. The Safety and Efficacy of Chronic Weekly Rozanolixizumab Treatment in Patients with Generalized Myasthenia Gravis (MG0004) (P4-14.017)
26. Epidemiology of myasthenia gravis in Denmark, Finland and Sweden: a population-based observational study
27. Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment
28. NEO1/NEO-EXT studies: Long-term muscle quantitative magnetic resonance imaging and functional efficacy in adults with late-onset Pompe disease (LOPD) on avalglucosidase alfa treatment
29. NEB mutations disrupt the super-relaxed state of myosin and remodel the muscle metabolic proteome in nemaline myopathy
30. Cardiac Outcomes in Adults With Mitochondrial Diseases
31. No effect of triheptanoin in patients with phosphofructokinase deficiency
32. Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis.
33. Clinical practice guidelines for glycogen storage disease V & VII (McArdle disease and Tarui disease) from an international study group
34. Nampt controls skeletal muscle development by maintaining Ca2+ homeostasis and mitochondrial integrity
35. Therapeutic advances in neuromuscular diseases in 2023
36. Plasma lactate responses during and after submaximal handgrip exercise are not diagnostically helpful in mitochondrial myopathy
37. Fatigue, physical activity and associated factors in 779 patients with myasthenia gravis
38. Rozanolixizumab responder and minimal symptom expression rates in generalized myasthenia gravis: Pooled phase 3 and extension studies
39. Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis regardless of prior treatment failures
40. Acetaminophen treatment in children and adults with spinal muscular atrophy: a lower tolerance and higher risk of hepatotoxicity
41. Fatigue and associated factors in 172 patients with McArdle disease: an international web-based survey
42. Skeletal Muscle Involvement in Patients With Truncations of Titin and Familial Dilated Cardiomyopathy
43. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
44. Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
45. Contractile properties and magnetic resonance imaging‐assessed fat replacement of muscles in myotonia congenita.
46. Defining clinical endpoints in limb girdle muscular dystrophy: a GRASP-LGMD study.
47. Burden of Disease of Duchenne Muscular Dystrophy in Denmark – A National Register-Based Study of Individuals with Duchenne Muscular Dystrophy and their Closest Relatives.
48. Autophagy is affected in patients with hypokalemic periodic paralysis: an involvement in vacuolar myopathy?
49. Autosomal dominant in cis D4Z4 repeat array duplication alleles in facioscapulohumeral dystrophy
50. Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.